Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/14897
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.otherUCH. Departamento de Ciencias Biomédicas-
dc.creatorEscudero Ortiz, Vanesa-
dc.creatorPérez Ruixo, Juan José-
dc.creatorValenzuela, Belén-
dc.date.accessioned2024-01-16T13:06:00Z-
dc.date.available2024-01-16T13:06:00Z-
dc.date.issued2015-04-
dc.identifier.citationEscudero-Ortiz, V., Pérez-Ruixo, J.J. & Valenzuela, B. (2015). Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice. Therapeutic Drug Monitoring, vol. 37, i. 2 (apr.), pp. 172–179. DOI: https://doi.org/10.1097/FTD.0000000000000121es_ES
dc.identifier.issn0163-4356-
dc.identifier.issn1536-3694 (Electrónico)-
dc.identifier.urihttp://hdl.handle.net/10637/14897-
dc.descriptionEste recurso no está disponible en acceso abierto por política de la editorial.-
dc.description.abstractBackground: Pazopanib, a new oral angiogenesis inhibitor, has demonstrated clinical activity against multiple solid tumors and was approved for the treatment of patients with advanced renal cell carcinoma. As an exposure-response relationship has been observed for pazopanib, its therapeutic drug monitoring could be a valuable tool in clinical practice. Therefore, the aim of this study was to develop and validate a selective and precise high performance liquid chromatography-ultraviolet method for the measurement of pazopanib in plasma from patients with cancer. Methods: After liquid-liquid extraction with diethyl ether, pazopanib and gefitinib (internal standard) were separated using isocratic elution on an Ultrabase C18 column using a mobile phase consisting of a mixture in vol/vol proportion of 47:53 of ammonium acetate (pH, 7; 0.02 mol/L) and acetonitrile/methanol (70:30, vol/vol) pumped at a constant flow rate of 1 mL/min. Quantification was performed at 260 nm. Method validation was undertaken as per the guidelines for Bioanalytical Method Validation published by the Food and Drug Administration and European Medicines Agency. Results: Calibration curves were linear over the range 0.5-100 mcg/mL. Interday and intraday coefficients of variations were less than 4.5%. The limit of detection and the lower limit of quantification were 0.2 and 0.5 mcg/mL, respectively. Recovery of pazopanib from plasma was >80%. Conclusions: This is the first high performance liquid chromatography-ultraviolet method for pazopanib quantification that has been validated within a wide range of plasma concentrations and is a suitable method for therapeutic drug monitoring of pazopanib.es_ES
dc.language.isoenes_ES
dc.publisherWolters Kluweres_ES
dc.relation.ispartofTherapeutic Drug Monitoring, vol. 37, i. 2 (apr.)-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.es-
dc.subjectCáncer-
dc.subjectCancer-
dc.subjectMedicamento-
dc.subjectDrugs-
dc.subjectTratamiento médico-
dc.subjectMedical treatment-
dc.titleDevelopment and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practicees_ES
dc.typeArtículoes_ES
dc.identifier.doihttps://doi.org/10.1097/FTD.0000000000000121-
dc.centroUniversidad Cardenal Herrera-CEU-
Aparece en las colecciones: Dpto. Ciencias Biomédicas




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.